Noxon

About

Funding history · 1 round · — total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Noxon's primary focus in drug development?

Noxon develops a novel drug for the oral treatment of fibrotic lung diseases.

What is the name of Noxon's main drug product?

Noxon's main drug product is 3-CP, which is a 3-cabamoyl-proxyl compound.

What unique property does Noxon's 3-CP drug possess?

Noxon's 3-CP drug has a unique antioxidant property.

What effects has Noxon's 3-CP drug demonstrated in animal models?

In animal models of allergic asthma, Noxon's 3-CP drug has been shown to reduce airway inflammation, airway hyper-responsiveness, and other inflammatory mediators of lung tissues.

When was Noxon founded?

Noxon was founded in January 2023.

What was Noxon's first funding round?

Noxon secured a Pre-Seed funding round in January 2023, with NGT HealthCare II as a lead investor.

What is Noxon's current funding stage?

Noxon is currently in the Pre-Seed funding stage.

Where is Noxon headquartered?

Noxon is headquartered in Nazareth, Israel, at Wadi el-Haj St 13.

How many employees does Noxon currently have?

Noxon currently has 6 employees.

Sectors & technology

Tags